Pfizer Inc. said a late-stage study found that its Lorbrena treatment reduced the risk of progression or death among lung-cancer patients by 72%.
The Phase 3 trial involved people with previously untreated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, Pfizer said Thursday.
The company still needs to figure out the overall survival of the drug trial, it said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.